Jennifer Lew Net Worth

The estimated Net Worth of Jennifer Lew is at least $2.07 Milión dollars as of 1 May 2019. Jennifer Lew owns over 18,602 units of Dynavax Technologies stock worth over $1,607,032 and over the last 15 years Jennifer sold DVAX stock worth over $460,264.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jennifer Lew DVAX stock SEC Form 4 insiders trading

Jennifer has made over 22 trades of the Dynavax Technologies stock since 2012, according to the Form 4 filled with the SEC. Most recently Jennifer exercised 18,602 units of DVAX stock worth $23,253 on 1 May 2019.

The largest trade Jennifer's ever made was exercising 18,750 units of Dynavax Technologies stock on 14 September 2012 worth over $10,125. On average, Jennifer trades about 4,766 units every 64 days since 2010. As of 1 May 2019 Jennifer still owns at least 147,299 units of Dynavax Technologies stock.

You can see the complete history of Jennifer Lew stock trades at the bottom of the page.

What's Jennifer Lew's mailing address?

Jennifer's mailing address filed with the SEC is C/O DYNAVAX TECHNOLOGIES, 2929 SEVENTH STREET, SUITE 100, BERKELEY, CA, 94710.

Insiders trading at Dynavax Technologies

Over the last 21 years, insiders at Dynavax Technologies have traded over $196,839,440 worth of Dynavax Technologies stock and bought 2,463,112 units worth $11,318,051 . The most active insiders traders include Andrew A. F. Hack, Partners L P/Ilbiotechnolog... a James Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $1,533,390. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth $43,127.

What does Dynavax Technologies do?

dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.

Complete history of Jennifer Lew stock trades at Aduro BioTech a Dynavax Technologies

Dynavax Technologies executives and stock owners

Dynavax Technologies executives and other stock owners filed with the SEC include:

• Ryan Spencer,
  CEO & Director
• David F. Novack,
  Pres & COO
• Dr. Robert Janssen,
  Chief Medical Officer and Sr. VP of Clinical Devel., Medical & Regulatory Affairs
• Michael S. Ostrach,
  Advisor
• John Slebir,
  Sr. VP & Gen. Counsel
• Nicole Arndt,
  Sr. Mang. of Investor Relations
• Meg Smith,
  VP Sales & Operations
• Steven N. Gersten,
  Chief Ethics & Compliance Officer, Sr. VP, Gen. Counsel and Sec.
• Heather Rowe,
  VP of Investor Relations & Corp. Communications
• Jeff P. Coon,
  Sr. VP of HR & Admin.
• Justin Burgess,
  Principal Accounting Officer & Controller
• Kelly MacDonald,
  Sr. VP & CFO
• Laura Brege,
  Director
• Eddie Gray,
  CEO and Director
• Arnold L Oronsky,
  Director
• Stanley A Plotkin,
  Director
• Daniel L Kisner,
  
• Dennis Carson,
  Director
• Natale S Ricciardi,
  Director
• David Louis Johnson,
  Vice President
• Michael S Ostrach,
  Senior Vice President
• Elaine D Sun,
  
• Francis Cano,
  
• Peter R. Paradiso,
  
• Peggy V Phillips,
  
• Brent Mac Gregor,
  
• Julia Marie Eastland,
  
• Scott Dunseth Myers,
  
• Partners L P/Ilbiotechnolog...,
  
• Nest Gary A Van,
  Vice President
• Dino Dina,
  President and CEO
• Denise Gilbert,
  Director
• Martin E Sanders,
  EVP, Chief Development Officer
• James Edeerfield Capital Lp...,
  
• Partners L P/Ilbiotechnolog...,
  
• James Edeerfield Capital Lp...,
  
• James Edeerfield Capital Lp...,
  
• Deborah A Smeltzer,
  VP Operations & CFO
• Timothy G Henn,
  Vice President
• Zbigniew Janowicz,
  Director
• Daniel Janney,
  Director
• Stephen F Tuck,
  Vice President
• Nancy L Buc,
  Director
• J Tyler Martin,
  VP Clinical Development & CMO
• Christine R Larson,
  VP and Chief Financial Officer
• Capital Partners Lpsymphony...,
  
• Jennifer Lew,
  VP, Finance & PAO
• Mark Kessel,
  Director
• David M Lawrence,
  Director
• Daniel J Levitt,
  VP and Chief Medical Officer
• James Edeerfield Capital Lp...,
  
• Louis C Bock,
  Director
• Jan Leschly,
  Director
• James E Flynn,
  10% owner
• Danielalta California Partn...,
  
• Robert Coffman,
  VP & Chief Scientific Officer
• David F Novack,
  President & COO
• Ryan Spencer,
  CEO and Director
• Robert Janssen,
  SVP and CMO
• Kelly Mac Donald,
  SVP and CFO
• Justin Burgess,
  VP Finance & CAO
• Andrew A. F. Hack,